科創新源(300731.SZ):222.376萬份股票權益解除限售條件成就
格隆匯7月20日丨科創新源(300731.SZ)公佈,公司2018年股票期權與限制性股票激勵計劃第一個行權期/解除限售期行權/解除限售條件成就。
公司2018年股票期權與限制性股票激勵計劃授予股票期權第一個行權期符合行權條件的激勵對象共計72人,可行權的期權數量為117.012萬份,佔公司總股本的比例為0.94%。第一個行權期的行權價格為20.27元/份,行權模式為集中行權。
公司本次激勵計劃授予限制性股票第一個解除限售期符合解除限售條件的激勵對象共計62人,可解除限售的限制性股票數量為105.364萬股,佔公司總股本比例為0.84%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.